Tubulis rides wave of ADC interest to $138M financing round
Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates
Most of the antibody-drug conjugate talk lately has been centered around Pfizer’s $43 billion deal with Seagen, but Bristol Myers Squibb is looking to up its game in the field by inking a modest upfront for work out of a German biotech.
Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer
MUNICH--(BUSINESS WIRE)--Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis’ proprietary pipeline of uniquely assembled antibody drug conjugates (ADCs), towards clinical evaluation as well as introduce programs addressing a range of solid tumor indications. The proceeds will enable the company to deliver the true therapeutic potential of ADCs through further innovation of novel payload classes and identification of new cancer targets.
MUNICH--(BUSINESS WIRE)--Tubulis today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and to further build the company’s clinical expertise. Dr. Fingerle-Rowson is an experienced hematologist and medical oncologist who brings to Tubulis more than two decades of academic, biotechnology and pharmaceutical industry experience. Moreover, he has a proven track record of advancing product candidates from early clinical phase through regulatory approval and into clinical practice. In this newly established role, he will use his extensive knowledge in the development of cancer therapeutics to oversee Tubulis’ clinical activities and advance the company’s Antibody Drug Conjugates (ADCs) towards clinical evaluation.